Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22014777 | 0.88 | — | — | |
| SCHEMBL20429952 | 0.83 | — | — | |
| SCHEMBL15821990 | 0.79 | LMNA (0.40) | LMNA | |
| SCHEMBL15821989 | 0.79 | LMNA (0.40) | LMNA | |
| SCHEMBL22722108 | 0.78 | — | — | |
| SCHEMBL11983845 | 0.77 | ALDH1A1 (0.41) | — | |
| SCHEMBL10709725 | 0.77 | — | — | |
| SCHEMBL19194058 | 0.75 | LMNA (0.32) | LMNA | |
| SCHEMBL5074508 | 0.75 | UGT2B7 (0.33) | — | |
| SCHEMBL256016 | 0.75 | ALDH1A1 (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11530209-B2 | Small molecule inhibition of transcription factor SALL4 and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-12-20 | — | — | US | disclosed |
| US-11236082-B2 | EZH2 inhibitors and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-20200338074-A1 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-10-29 | — | — | US | disclosed |
| US-10702527-B2 | Combination therapy of transcription inhibitors and kinase inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-07-07 | — | — | US | disclosed |
| US-20190192532-A1 | COMBINATION THERAPY OF BROMODOMAIN INHIBITORS AND CHECKPOINT BLOCKADE | PETER MACCALLUM CANCER INSTITUTE (AU) | 2019-06-27 | — | — | US | disclosed |
| US-10308653-B2 | Diazepane derivatives and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-20190015411-A9 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-01-17 | — | — | US | disclosed |
| US-20180169097-A1 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-06-21 | — | — | US | disclosed |
| US-20180169097-A1 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-06-21 | — | — | US | disclosed |
| US-9951074-B2 | Dihydropteridinone derivatives and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-20170145023-A1 | DIAZEPANE DERIVATIVES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-05-25 | — | — | US | disclosed |
| US-9540317-B2 | Class- and isoform-specific HDAC inhibitors and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-01-10 | — | — | US | disclosed |
| US-20150307444-A1 | CLASS- AND ISOFORM-SPECIFIC HDAC INHIBITORS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2015-10-29 | — | — | US | disclosed |
| US-20150173359-A1 | SUBSTITUTED FUSED PYRIMIDINONES AND DIHYDROPYRIMIDINONES | BAYER IP GMBH (DE) | 2015-06-25 | — | — | US | disclosed |
| US-20150173359-A1 | SUBSTITUTED FUSED PYRIMIDINONES AND DIHYDROPYRIMIDINONES | BAYER IP GMBH (DE) | 2015-06-25 | — | — | US | disclosed |
| US-9006265-B2 | Substituted fused pyrimidinones and dihydropyrimidinones | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-04-14 | — | — | US | disclosed |
| US-9006265-B2 | Substituted fused pyrimidinones and dihydropyrimidinones | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-04-14 | — | — | US | disclosed |
| US-8716344-B2 | Class- and isoform-specific HDAC inhibitors and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2014-05-06 | — | — | US | disclosed |
| US-20120208889-A1 | CLASS- AND ISOFORM-SPECIFIC HDAC INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUE, INC. (US) | 2012-08-16 | — | — | US | disclosed |
| US-20120157306-A1 | Substituted Fused Pyrimidinones and Dihydropyrimidinones | BAYER CROPSCIENCE AG (DE) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150173359-A1 | SUBSTITUTED FUSED PYRIMIDINONES AND DIHYDROPYRIMIDINONES | DHPS, FDPS, DPYD | LMNA 4551/4885 |
| US-10308653-B2 | Diazepane derivatives and uses thereof | BRDT, BRD4, BAZ2A | LMNA 744/4885 |
| US-10702527-B2 | Combination therapy of transcription inhibitors and kinase inhibitors | CHUK, BCOR, MYC | LMNA 2211/4885 |
| US-20180169097-A1 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | CHUK, BCOR, MYC | LMNA 2211/4885 |
| US-20150307444-A1 | CLASS- AND ISOFORM-SPECIFIC HDAC INHIBITORS AND USES THEREOF | HDAC1, HDAC5, HDAC6 | LMNA 1808/4885 |
| US-20120157306-A1 | Substituted Fused Pyrimidinones and Dihydropyrimidinones | DHPS, FDPS, DPYD | LMNA 4551/4885 |
| US-20190015411-A9 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | CHUK, BCOR, MYC | LMNA 2211/4885 |
| US-20120208889-A1 | CLASS- AND ISOFORM-SPECIFIC HDAC INHIBITORS AND USES THEREOF | HDAC1, HDAC5, HDAC6 | LMNA 1808/4885 |
| US-20190192532-A1 | COMBINATION THERAPY OF BROMODOMAIN INHIBITORS AND CHECKPOINT BLOCKADE | BRD4, BRD3, BRPF3 | LMNA 4249/4885 |
| US-11530209-B2 | Small molecule inhibition of transcription factor SALL4 and uses thereof | SALL4, GLI2, TCF4 | LMNA 3745/4885 |
| US-11236082-B2 | EZH2 inhibitors and uses thereof | EZH2, EZH1, BMI1 | LMNA 2203/4885 |
| US-20200338074-A1 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | CHUK, BCOR, MYC | LMNA 2211/4885 |
| US-20170145023-A1 | DIAZEPANE DERIVATIVES AND USES THEREOF | BRDT, BRD4, BAZ2A | LMNA 744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.